Skip to main navigation Skip to search Skip to main content

Emergence of fluoroquinolone-resistant tuberculosis in New York City

  • E. A. Sullivan
  • , L. Palumbo
  • , A. Ebrahimzadeh
  • , T. R. Frieden
  • , E. A. Sullivan
  • , T. R. Frieden
  • , B. N. Kreiswirth
  • , V. Kapur
  • , J. M. Musser

Research output: Contribution to journalArticlepeer-review

Abstract

22 patients infected with fluoroquinolone-resistant Mycobacterium tuberculosis in New York City were identified between January, 1991, and November, 1993. In 16 patients resistance arose as a result of inadequate or inappropriate treatment. 6 patients had primary infection with fluoroquinolone-resistant organisms; 5 acquired the organisms nosocomially. Seven distinct patterns of restriction-fragment length polymorphism were identified in isolates from 21 patients. Fluoroquinolones should be restricted to patients with multidrug-resistant disease or intolerance to other antituberculosis drugs. All patients with multidrug-resistant tuberculosis should be on directly observed therapy.

Original languageEnglish (US)
Pages (from-to)1148-1150
Number of pages3
JournalThe Lancet
Volume345
Issue number8958
DOIs
StatePublished - May 6 1995

All Science Journal Classification (ASJC) codes

  • General Medicine

Fingerprint

Dive into the research topics of 'Emergence of fluoroquinolone-resistant tuberculosis in New York City'. Together they form a unique fingerprint.

Cite this